AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00900965 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))
Description: A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
Study NCT00900965 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))
Description: Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
Study NCT00404261 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluticasone/Salmeterol HFA
Description: Fluticasone/Salmeterol HFA, 2 puffs twice daily
Study NCT03522935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous.
Study NCT02704975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation and Dry Needling
Description: Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months. Subjects in this group will also receive dry needling as an adjunct intervention. Dry needling treatment will be performed one time a week for four weeks and will begin four weeks post-operative.
Study NCT02704975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months.
Study NCT01541007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: 25 mg/m2 every three weeks
Study NCT01541007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: weekly cabazitaxel
Description: 10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks
Study NCT01018173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sc weekly
Study NCT01018173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10 mg sc weekly for 4 weeks, followed by 20 mg sc weekly
Study NCT03780621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrographis and Withania
Description: Combination of Andrographis paniculata and Withania somnifera
Study NCT03780621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually identical placebo capsule
Study NCT02154334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone
Description: Healthy participants will self-administer 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril prior to 1 intranasal spray of esketamine solution 14 mg in each nostril at Time 0 and 5 minutes for a total dose of 56 mg on Day 16 in Period 2.
Study NCT04071561 — intervention group
Intervention type: OTHER
Intervention: Posterior retroperitoneal adrenalectomy (PRA)
Description: Minimally invasive adrenalectomy procedure
Study NCT04071561 — intervention group
Intervention type: OTHER
Intervention: Lateral transperitoneal adrenalectomy (LTA)
Description: During posterior retroperitoneal adrenalectomy, the failure to progress or the difficulty of creating or maintaining a pneumoperitoneum are reasons why conversion occurs.
Study NCT04286243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based HPV screening strategy
Description: Offering HPV self-collection for cervical cancer screening in the community
Study NCT04944238 — intervention group
Intervention type: DEVICE
Intervention: Ankoris
Description: Implantations of test lens using standard phaco surgical technique, with aim for in-the-bag implantation.
Study NCT04188834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized version of DAVID device
Description: A customized version of the DAVID device will be used to expose participants to sensory flicker. The device consists of opaque glasses containing LEDs to present flickering light, as well as earbuds or headphones to present flickering sound.
Study NCT04188834 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blackrock CereStim
Description: The Blackrock CereStim is a fully programmable neurostimulator. The current pulses generated by the Blackrock CereStim are intended to stimulate neurons in proximity to a set of electrodes.
Study NCT00770627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 caps
Description: Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day
Study NCT00770627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega 3 caps
Description: Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day
Study NCT03755219 — intervention group
Intervention type: PROCEDURE
Intervention: TEP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
Study NCT04286243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic-based HPV screening strategy
Description: Offering HPV self-collection for cervical cancer screening in the clinic
Study NCT02429544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Residential Program
Description: Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.
Study NCT02429544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed about mood, sleep, fatigue, how participant has been feeling, and their general quality of life at baseline visit, 1 month after baseline, 7 days after residential program ends, and again about 3 months later.
Study NCT03755219 — intervention group
Intervention type: PROCEDURE
Intervention: TAPP
Description: By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
Study NCT02429544 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires completed about mood, sleep, fatigue, how participant has been feeling, and their general quality of life at baseline visit, 1 month after baseline, 7 days after residential program ends, and again about 3 months later.
Study NCT02429544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram (EEG)
Description: EEG performed at baseline with simultaneous computer testing consisting of 3 tests to check attention, short-term memory, and levels of emotions. EEG repeated 7 days after the residential program ends, and then again about 3 months later.
Study NCT02429544 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electroencephalogram (EEG)
Description: EEG performed at baseline with simultaneous computer testing consisting of 3 tests to check attention, short-term memory, and levels of emotions. EEG repeated 7 days after the residential program ends, and then again about 3 months later.
Study NCT02429544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Testing
Description: Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. Saliva testing repeated 7 days after the residential program ends, and then again about 3 months later.
Study NCT02429544 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Saliva Testing
Description: Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. Saliva testing repeated 7 days after the residential program ends, and then again about 3 months later.
Study NCT02429544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Diary plus Actigraph
Description: For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
Study NCT02429544 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Study Diary plus Actigraph
Description: For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
Study NCT04101461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron
Description: PharaFerro27; Devart Lab Company, Egypt
Study NCT04101461 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Complete blood count
Description: to assess the anemia
Study NCT04101461 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum ferritin
Description: to assess the anemia
Study NCT04101461 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum hepcidin
Description: to assess the iron abosrption
Study NCT04101461 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum Iron
Description: to assess the anemia
Study NCT04101461 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum total iron binding capacity
Description: to assess the anemia
Study NCT00694577 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation using 32 Gy / 8 fractions
Description: 32 Gy-8 Treatments, 4 Treatment Days
Study NCT00694577 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation using 36 Gy / 9 fractions
Description: 36 Gy- 9 Treatments, 4 1/2 Treatment Days
Study NCT01044771 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: change from tenofovir to raltegravir
Description: Change of the tenofovir based nucleoside part of the HIV regimen to raltegravir, 400mg BID
Study NCT04379024 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DUAVEE 0.45Mg-20Mg Tablet
Description: One capsule daily for 6 months (+/- 1 month)
Study NCT04379024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUAVEE 0.45Mg-20Mg Tablet
Description: One capsule daily for 6 months (+/- 1 month)
Study NCT00694577 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation using 40 Gy /10 fractions
Description: 40 Gy-10 Treatments, 5 Treatment days
Study NCT02154334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Description: Nasal rhinitis participants will self-administer 2 intranasal sprays of Oxymetazoline 0.05% w/v solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1or Period 2.
Study NCT01924039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Enhancement Therapy
Description: The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.
Study NCT01924039 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Motivational Enhancement Therapy
Description: The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.
Study NCT01924039 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: treatment as usual
Description: Treatment as usual includes case management as well as psychiatric appointments.
Study NCT02952313 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal Implant
Study NCT01969968 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lipophilic Organic Polluants dosage
Description: Urinary, blood and fat dosage of Lipophilic Organic Polluants
Study NCT02069821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination administration
Description: combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)
Study NCT00705445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Supplementation without Zinc
Description: This will contain Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D and Folic Acid
Study NCT00705445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Supplementation with Zinc
Description: This will contain Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid. Additionally, this will also contain 10 mg elemental Zinc Sulphate.
Study NCT00705445 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counselling and Education
Description: This will contain Nutritional Counselling and Education.
Study NCT01271907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine 25 mg/m\^2 x 5 days
Study NCT01271907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide 60 mg/kg intravenous (IV) x 2 days
Study NCT01271907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL
Description: Up to 1x10e10 CTL-05 cells
Study NCT01271907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
Study NCT00932438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LC beads loaded with Irinotecan
Description: Chemoembolization using LC beads loaded with 100mg Irinotecan
Study NCT00932438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/sqm, IV infusion every two weeks
Study NCT00932438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/sqm, IV infusion every two weeks
Study NCT00932438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Leucovorin 200 mg/sqm, IV infusion every two weeks
Study NCT02740712 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Caffeine
Description: 200 mg (4 x 50mg) Tablet
Study NCT00932438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 200 mg/sqm, IV infusion every two weeks
Study NCT00932438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week
Study NCT00932438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week
Study NCT00932438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg given at the discretion of the treating physician
Study NCT00932438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg given at the discretion of the treating physician
Study NCT02403063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
Study NCT02403063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Administration of neostigmine 50µg/kg for enhanced recovery after neuromuscular blockade with rocuronium
Study NCT02403063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine-sugammadex
Description: Administration of neostigmine 50µg/kg followed 3 minutes later by administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
Study NCT02833584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol 500 mg x 1 tablets according to patient's body weight
Study NCT02833584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 500 mg x 1 tablets according to patient's body weight
Study NCT00982046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free RepleniSH multi-purpose disinfecting solution
Description: Contact lens solution CE-marked for intended use.
Study NCT03524898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: 150 mg/m2 / 125 mg/m2
Study NCT02740712 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Description: 10 mg (2 x 5mg) Tablet
Study NCT02740712 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: 40 mg Tablet
Study NCT02740712 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: 5 mg/mL
Study NCT02740712 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: digoxin
Description: .25 mg Tablet
Study NCT02740712 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin K
Description: 10 mg Tablet
Study NCT02740712 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rucaparib
Description: 200 \& 300 mg tablet
Study NCT02774044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadisurf
Description: Cadisurf Intratracheal suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural lung extract containing phospholipids and surfactant-associated proteins. The resulting composition provides 25 mg/mL phospholipids and less than 1.0 mg/ml protein. It is suspended in 0.9% sodium chloride solution. Cadisurf contains no preservatives. Each ml of Cadisurf contains 25 mg of phospholipids. It is a creamy white suspension supplied in single-use glass vials containing 8 mL (200 mg phospholipids).
Study NCT02774044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Survanta
Study NCT04062799 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: It is an observationa study. There is no intervention.
Study NCT03524898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m2
Study NCT00982046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus multi-purpose solution
Description: Contact lens solution CE-marked for intended use.
Study NCT00982046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care cleaning and disinfecting system
Description: Contact lens care system CE-marked for intended use.
Study NCT00982046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A contact lens (ACUVUE OASYS)
Description: Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
Study NCT00982046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B contact lens (AIR OPTIX AQUA)
Description: Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
Study NCT00982046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lens (Biofinity)
Description: Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
Study NCT01808638 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atu027 & gemcitabine in lead in safety period
Description: Subjects will be treated in a 28-day cycle with Atu027 twice weekly for 4 weeks and gemcitabine once weekly for the first three weeks.
Study NCT01808638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atu027 & gemcitabine in treatment arm 1
Description: Subjects will be treated in a 28-day cycle with Atu027 and gemcitabine once weekly for three consecutive weeks (on days 1, 8, and 15). During week four no treatment is administered.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs.
Study NCT01808638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atu027 & gemcitabine in treatment arm 2
Description: Subjects will be treated in a 28-day cycle with gemcitabine once weekly (on days 4, 11, and 18) and Atu027 twice weekly (on days 1, 4, 8, 11, 15, 18, 22, and 25). The 28-day combination cycle is followed by a 28-day gemcitabine monotherapy cycle.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs.